PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect

Authors :: Xuejun Wen
Xueyuan Zeng
Xingxing Cheng
Xinying Zeng
Jia Liu
Yiren Zhang
Yesen Li
Haojun Chen
Jinxiong Huang
Zhide Guo
Xiaoyuan Chen
Xianzhong Zhang
Source :: Molecular Pharmaceutics. 19:3612-3622
Publication Year :: 2022
Publisher :: American Chemical Society (ACS), 2022.
Abstract: Immune checkpoint blockers (ICBs) targeting programmed death receptor 1 (PD-1) ligand 1 (PD-L1) for immunotherapy have radically reformed oncology. It is of great significance to enhance the response rate of ICB in cancer patients. Here, a radioiodinated anti-PD-L1 antibody (

Subjects :: Programmed Cell Death 1 Receptor
Pharmaceutical Science
Receptors, Death Domain
Ligands
Antibodies
Iodine Radioisotopes
Mice
Cell Line, Tumor
Neoplasms
Drug Discovery
Animals
Humans
Immunologic Factors
Molecular Medicine
Immunotherapy
Immune Checkpoint Inhibitors

Tools